STAT活化抑制蛋白2基因在前列腺癌中的表达水平及与临床病理特征的关系

doi:10.3969/j.issn.1006-5725.2025.18.009

Abstract

Abstract:

Objective To investigate the expression level of the protein inhibitor of the activated STAT2 （PIAS2） gene in prostate cancer and its relationship with clinicopathological features， and the potential role of PIAS2 in reprogramming lipid metabolism in prostate cancer. Methods The Cancer Genome Atlas Program （TCGA） database and HPA immunohistochemical analysis were used to show the expression of PIAS2 protein； qRT-PCR， Western bolt and immunohistochemistry were used to detect PIAS2 in prostate cancer tissues and their paracancerous tissues. PIAS2 expression in prostate cancer tissues and its paracancerous tissues and analyzed its relationship with clinicopathological features of patients； lentivirus infected prostate cancer cell line PC-3M， which stably knocked down PIAS2， was analyzed by ultra performance liquid chromatography mass spectrometry （UPLC-MS） for lipidomics. Results TCGA analysis showed that the expression of PIAS2 in prostate cancer tissues was higher than that in paracancerous tissues， and HPA immunohistochemistry analysis showed that PIAS2 protein was highly expressed in prostate cancer tissues； the expression of PIAS2 mRNA and protein was significantly elevated in prostate cancer compared with that in paracancerous tissues， and the difference was statistically significant （P < 0.05）； immunohistochemistry showed that PIAS2 protein Expression of PIAS2 protein was mainly localized in the nucleus of prostate， and the AOD value of prostate cancer tissues was significantly higher than that of paraneoplastic tissues： the results of clinicopathological parameters showed that PIAS2 had correlation with Gleason score and TNM stage （P < 0.05）， while there was no statistically significant correlation with the age of the patients， PSA and lymph node metastasis； UPLC-MS analysis suggested that the knockdown of PIAS2 affected 10 lipid changes， with down-regulation of phosphatidylcholine and phosphatidylethanolamine and up-regulation of phosphatidylinositol， phosphatidylserine， diacylglycerol， and triacylglycerol in the shPIAS2 group compared with the shNC group. Conclusions The expression of PIAS2 protein was significantly elevated in prostate cancer tissues， suggesting that PIAS2 is associated with the development of prostate cancer， and its pathogenesis may be related to the abnormal lipid metabolism of prostate cancer.

Key words: prostate cancer, STAT activation inhibitory protein 2, immunohistochemistry, lipid metabolism reprogramming

CLC Number:

R737.25

Weizun LI,Chen XING,Hengqing AN. STAT activation inhibitory protein 2 is involved in reprogramming of lipid metabolism by regulating the prostate cancer development[J]. The Journal of Practical Medicine, 2025, 41(18): 2844-2852.

Figures/Tables 7

Tab.1

Fig.1

Fig.2

Tab.2

Fig.3

Fig.4

Fig.5

References 30

[1]	CAO W， CHEN H D， YU Y W， et al. Changing profiles of cancer burden worldwide and in China： A secondary analysis of the global cancer statistics 2020［J］. Chin Med J （Engl）， 2021， 134（7）： 783-791. doi:10.1097/cm9.0000000000001474 doi: 10.1097/cm9.0000000000001474
[2]	LI X， RASUL A， SHARIF F， et al. PIAS family in cancer： From basic mechanisms to clinical applications［J］. Front Oncol， 2024， 14： 1376633. doi:10.3389/fonc.2024.1376633 doi: 10.3389/fonc.2024.1376633
[3]	GHAFOURI-FARD S， HUSSEN B M， NICKNAFS F， et al. Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy［J］. Front Immunol， 2021， 12：659038. doi:10.3389/fimmu.2021.659038 doi: 10.3389/fimmu.2021.659038
[4]	MAGALHAES J， TRESSE E， EJLERSKOV P， et al. PIAS2-mediated blockade of IFN-β signaling： A basis for sporadic Parkinson disease dementia［J］.Mol Psychiatry， 2021， 26（10）： 6083-6099. doi:10.1038/s41380-021-01207-w doi: 10.1038/s41380-021-01207-w
[5]	LI C， BOUTET A， PASCARIU C M， et al. SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation［J］. J Proteome Res， 2023， 22（3）： 812-825. doi:10.1021/acs.jproteome.2c00557 doi: 10.1021/acs.jproteome.2c00557
[6]	KUKKULA A， OJALA V K， MENDEZ L M， et al. Therapeutic Potential of Targeting the SUMO Pathway in Cancer［J］. Cancers （Basel）， 2021， 13（17）：4402. doi:10.3390/cancers13174402 doi: 10.3390/cancers13174402
[7]	RODRIGUES J S， CHENLO M， BRAVO S B， et al. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe［J］. Nat Commun， 2024， 15（1）： 3736. doi:10.1038/s41467-024-50135-0 doi: 10.1038/s41467-024-50135-0
[8]	LIANG J， LI L， LI L， et al. Lipid metabolism reprogramming in head and neck cancer［J］. Front Oncol， 2023， 13： 1271505. doi:10.3389/fonc.2023.1271505 doi: 10.3389/fonc.2023.1271505
[9]	TANG M， LI X， REN J， et al. Limosilactobacillus reuteri HM108 alleviates obesity in rats fed a high-fat diet by modulating the gut microbiota， metabolites， and inhibiting the JAK-STAT signalling pathway［J］. Front Nutr， 2025， 12：1597334. doi:10.3389/fnut.2025.1597334 doi: 10.3389/fnut.2025.1597334
[10]	KONG X， CHEN H， LI D， et al. Effects of imbalance of lipid metabolism through NF-κB pathway on atherosclerosis and vascular aging in rats［J］. Cell Mol Biol （Noisy-le-grand）， 2022， 67（5）： 144-150. doi:10.14715/cmb/2021.67.5.20 doi: 10.14715/cmb/2021.67.5.20
[11]	杨剑波，邵继春，曾治军，等. lncRNA MIF-AS1调节miR-423-5p/PYCR1轴对前列腺癌细胞恶性生物学行为的影响［J］. 实用医学杂志， 2024， 40（18）： 2544-2549.
[12]	SHU H， CHEN X， ZHAO J， et al. PIAS family gene expression： Implications for prognosis， immunomodulation， and chemotherapy response［J］. Am J Transl Res， 2024， 16（11）： 6346-6364. doi:10.62347/jrdp4018 doi: 10.62347/jrdp4018
[13]	PENG Y， LEE J， ZHU C， et al. A novel role for protein inhibitor of activated STAT （PIAS） proteins in modulating the activity of Zimp7， a novel PIAS-like protein， in androgen receptor-mediated transcription［J］. J Biol Chem， 2010， 285（15）： 11465-11475. doi:10.1074/jbc.m109.079327 doi: 10.1074/jbc.m109.079327
[14]	杨锐，易成，陈钢鑫，等. PIAS2蛋白和生精细胞凋亡在无精子症中相关性的研究［J］. 中国优生与遗传杂志， 2022， 30（7）： 1177-1181.
[15]	DU J， DU Y， CHEN L， et al. IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5［J］. Biochim Biophys Acta Mol Cell Res， 2023， 1870（7）： 119547. doi:10.1016/j.bbamcr.2023.119547 doi: 10.1016/j.bbamcr.2023.119547
[16]	LI Y， LIN H， SHU S， et al. Integrative transcriptome analysis reveals TEKT2 and PIAS2 involvement in diabetic nephropathy［J］. FASEB J，2022，36（11）：e22592. doi:10.1096/fj.202200740rr doi: 10.1096/fj.202200740rr
[17]	WADA H， SUZUKI D， NIIKURA T. Regulation of ALS-Associated SOD1 Mutant SUMOylation and Aggregation by SENP and PIAS Family Proteins［J］. J Mol Neurosci，2020，70（12）：2007-2014. doi:10.1007/s12031-020-01604-w doi: 10.1007/s12031-020-01604-w
[18]	GHAFOURI-FARD S， HESAMI O， NAZER N， et al. Expression of PIAS Genes in Migraine Patients［J］. J Mol Neurosci， 2021， 71（10）： 2053-2059. doi:10.1007/s12031-021-01834-6 doi: 10.1007/s12031-021-01834-6
[19]	LIU Y， LIAO S， BENNETT S， et al. STAT3 and its targeting inhibitors in osteosarcoma［J］.Cell Prolif， 2021， 54（2）： e12974. doi:10.1111/cpr.12974 doi: 10.1111/cpr.12974
[20]	MOHAN C D， RANGAPPA S， NAYAK S C， et al. Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma［J］. Biochim Biophys Acta Rev Cancer， 2021， 1876（1）： 188574. doi:10.1016/j.bbcan.2021.188574 doi: 10.1016/j.bbcan.2021.188574
[21]	WU R， FANG J， LIU M， et al. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1， UBC9， and PIAS2 and enhances its stability and function in cell proliferation［J］.J Biol Chem，2020， 295（19）：6741-6753. doi:10.1074/jbc.ra119.012338 doi: 10.1074/jbc.ra119.012338
[22]	CHEN S Y， CHIANG C F， SU Y F， et al. Protein inhibitor of activated signal transducer and activator of transcription 2 is an oncoprotein in oral squamous cell carcinoma and related to cigarette smoking - An in vitro study［J］. J Dent Sci， 2024， 19（4）： 1983-1990. doi:10.1016/j.jds.2024.07.013 doi: 10.1016/j.jds.2024.07.013
[23]	PENNEY K L， TYEKUCHEVA S， ROSENTHAL J， et al. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum［J］.Mol Cancer Res， 2021， 19（3）： 475-484. doi:10.1158/1541-7786.mcr-20-0548 doi: 10.1158/1541-7786.mcr-20-0548
[24]	徐焕铭. CRNDE调控PIAS2介导急性髓细胞白血病预后调节机制的研究［D］. 沈阳：中国医科大学， 2021.
[25]	贾雯茜. STAT3介导苏氨酸调控HepG2细胞甘油三酯沉积［D］. 扬州：扬州大学， 2024.
[26]	YANG M， WU S， CAI W， et al. Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6/JAK-STAT pathway［J］.Lipids Health Dis， 2022，21（1）： 82. doi:10.1186/s12944-022-01693-z doi: 10.1186/s12944-022-01693-z
[27]	STOICA C， FERREIRA A K， HANNAN K， et al. Bilayer forming phospholipids as targets for cancer therapy［J］. Int J Mol Sci， 2022， 23（9）： 5266. doi:10.3390/ijms23095266 doi: 10.3390/ijms23095266
[28]	LIU Q， ZHANG X， QI J， et al. Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC［J］. Hepatology， 2025， 81（4）： 1164-1180. doi:10.1097/hep.0000000000000962 doi: 10.1097/hep.0000000000000962
[29]	LI X， NAKAYAMA K， GOTO T， et al. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer［J］. Cancer Sci， 2021， 112（10）： 4292-4302. doi:10.1111/cas.15093 doi: 10.1111/cas.15093
[30]	GUAN Y， CHEN X， WU M， et al. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy［J］. J Hepatol， 2020， 72（4）： 746-760. doi:10.1016/j.jhep.2019.11.007 doi: 10.1016/j.jhep.2019.11.007

实验材料	购买平台
胎牛血清	上海瑞博赛生物科技有限公司
RPMI-1640培养基	美国海克隆公司
双抗、胰酶	上海碧云天生物科技有限公司
SDS-PAGE凝胶制备试剂盒、BCA蛋白定量试剂盒、蛋白取样缓冲液	北京索莱宝公司
PCR相关试剂盒	中国北京Takara公司
Trizol RNA提取试剂	美国Invitrogen公司
GAPDH单克隆抗体	英国Abcam公司
PIAS2多克隆抗体	中国Abclonal公司
PBS、过氧化氢、通用二抗	中国中杉金桥公司
PIAS2和GAPDH引物	上海生工生物技术有限公司

临床病理参数	例数	PIAS2表达		χ² 值	P值
临床病理参数	例数	高表达	低表达	χ² 值	P值
类型				13.833	0.010
癌组织	65	39	26
癌旁组织	65	19	46
年龄				1.659	0.421
≤ 60岁	30	17	13
> 60岁	35	23	12
Gleason评分				7.342	0.041
≤ 8	19	10	9
> 8	46	22	24
PSA				1.213	0.254
≤ 20 ng/mL	38	21	17
> 20 ng/mL	27	13	14
TNM分期				8.153	0.038
Ⅰ + Ⅱ	23	10	13
Ⅲ + Ⅳ	42	25	17
淋巴结转移				2.553	0.307
否	41	24	17
是	24	13	11

STAT activation inhibitory protein 2 is involved in reprogramming of lipid metabolism by regulating the prostate cancer development

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 30

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xifeng XU,Xia WANG,Jianliang WU,Jinlong. CHENG. Effect of immunohistochemical detection of omentin-1， SPP1 and MMR protein expression status on clinicopathological features and prognosis analysis of endometrial cancer [J]. The Journal of Practical Medicine, 2025, 41(16): 2521-2527.
[2]	Junzhi LIU,Lei QIU,Kun XU,Jianwei LIU,Dehua HU,Hua ZHU,Cheng SHEN,Ming LU,Jiangang. CHEN. Establishment of a nomogram model for predicting pelvic lymph node metastasis in prostate cancer based on systemic immune-infiltration inflammation index [J]. The Journal of Practical Medicine, 2025, 41(15): 2349-2354.
[3]	Hongchao SHAO,Qiyuan LUO,Wenbin GAO,Wen LUO,Mushi YE. Resveratrol inhibits prostate cancer growth and hormone resistance： An in vivo study [J]. The Journal of Practical Medicine, 2025, 41(12): 1835-1839.
[4]	Weifeng LIU,Zheng DAI,Yibin ZHOU,Kaiwen FENG,Kai WEI,Gule SUN,Dongrong YANG,Jin. ZHU. The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer [J]. The Journal of Practical Medicine, 2024, 40(5): 688-694.
[5]	Canwei CHEN,Zhuangwen LIAO,Ziwen FAN,Shuai HUANG,Yan HUANG,Binwei CHEN. LAMP3 inhibited the proliferation， metastatic and PC⁃3⁃induced vasculogenesis of HUVEC by regulating VEGF/AKT signaling [J]. The Journal of Practical Medicine, 2024, 40(2): 182-187.
[6]	Jianbo YANG,Jichun SHAO,Zhijun ZENG,Tao ZHAO,Xing. WANG. Effect of lncRNA MIF⁃AS1 on the malignant biological behavior of prostate cancer cells by regulating the miR⁃423⁃5p/PYCR1 axis [J]. The Journal of Practical Medicine, 2024, 40(18): 2544-2549.
[7]	Zhishi WANG,Guiling LI,Jingguo CHEN,Hong. WANG. Effects of miR⁃223 on prostate cancer cell damage by regulating Keap1/Nrf2/ARE signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(17): 2375-2380.
[8]	DING Qi, SUN Mubin, JIN Xiaohua, FAN Zhijiang, TU Wenjian, LI Feng, SHI Yi, FAN Bo.. Efficacy and prognosis of cytoreductive radical prostatectomy combined with androgen deprivation therapy for oligometastatic prostate cancer [J]. The Journal of Practical Medicine, 2023, 39(4): 460-464.
[9]	Minyu HUANG,Jun WU,Tianzi QIN,Wei ZHOU,Lize SU,Rong QIU,Lu. HUANG. The prognostic value of serum DCLK1 and sTim⁃3 in patients undergoing radical prostatectomy for prostate cancer [J]. The Journal of Practical Medicine, 2023, 39(18): 2368-2372.
[10]	ZHAO Haijun, LI Wei, WEI Yu, ZHANG Licui, ZHANG Yu, WANG Xinmin, WANG Cuizhe. . Effect of vitamin D on bone metastasis of prostate cancer mice induced by octanoic acid and high⁃fat diet [J]. The Journal of Practical Medicine, 2023, 39(14): 1756-1761.
[11]	HUANG Wei, FU Weijin, ZHANG Mingjin, YANG Xiaoli. . Research progress of pembrolizumab in the treatment of castration ⁃ resistant prostate cancer [J]. The Journal of Practical Medicine, 2023, 39(11): 1376-1382.
[12]	HUANG Shuai, HUANG Guoliang, LINGHU Xitao, XIE Shangyan, WA Qingde, GUO Yuanqing, HUANG Yan.. Study on the effect of betulinic acid on the biological behavior and osteoclast differentiation of PC⁃3 cells in acidic microenvironment [J]. The Journal of Practical Medicine, 2022, 38(9): 1076-1081.
[13]	CHEN Canwei, FAN Ziwen, HUANG Shuai, HUANG Yan, WA Qingde, LINGHU Xitao, LIAO Zhuangwen. . Effects of Diosmetin on proliferation，apoptosis，colony ⁃ formation，migration and cells adhesion of pros⁃ tate cancer PC⁃3 cells [J]. The Journal of Practical Medicine, 2022, 38(6): 721-725.
[14]	HUANG Sheng, GONG Rui, LIU Gangan, QI Qihua, HUANG Shuai. Effect of deoxyschizandrin on proliferation，migration and invasion of PC ⁃ 3 cells and its mechanism [J]. The Journal of Practical Medicine, 2021, 37(7): 851-857.
[15]	ZHANG Chaojie, YAN Hongjuan, ZHAO Juhong, ZHANG Jie, LI Chaoyang, XU Jiang.. Expression and clinical significance of FOXP3 in oral squamous cell carcinoma [J]. The Journal of Practical Medicine, 2021, 37(7): 939-938.